$ATTO News

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Attovia Therapeutics To Present New Clinical, Translational, And Preclinical Data Across Its Pipeline At EADV Congress And FCD 2026

Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics Q2 EPS $(4.88) Misses $(4.62) Estimate, Sales $450.000K

Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says

Citigroup Initiates Coverage On Attovia Therapeutics with Buy Rating, Announces Price Target of $30

LifeSci Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

Leerink Partners Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $52

RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45

Morgan Stanley Initiates Coverage On Attovia Therapeutics with Overweight Rating, Announces Price Target of $39

Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source

Attovia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immune Mediated Disease Therapeutics Developer Attovia Therapeutics Debuts on Nasdaq

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Attovia Therapeutics Begins IPO Effort On Promising Early Trials

NYSE To Commence Delisting Proceedings Against Atento S.A.

Watching Atento S.A.; Stock Price Moving Higher As Traders Circulate Co Website, Mentioned As AI-Related In The Cyber Security Space; Shares Up 100%